U.S. Reps. David McKinley (R-W.Va.) and Abigail Spanberger’s (D-Va.) bipartisan PROTECT 340B Act (H.R. 4390) can “resolve two of the most intractable challenges in the 340B program in one fell swoop” while satisfying both covered entities and drug manufacturers, 340B Report Publisher and CEO Ted Slafsky says in his latest column for Omnicell.
Slafsky says the two perennial challenges are (1) payer and pharmacy benefit manager contract terms that transfer 340B savings from covered entities to payers and PBMs, and (2) drug manufacturer exposure to duplicate 340B discounts and Medicaid rebates on the same drugs.
U.S. Reps. David McKinley (R-W.Va.) and Abigail Spanberger’s (D-Va.) bipartisan PROTECT 340B Act (H.R. 4390) can “resolve two of the most intractable challenges in the 340B program in one fell swoop” while satisfying both covered entities and drug manufacturers, 340B Report Publisher and CEO Ted Slafsky says in his latest column for Omnicell.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
